Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-01-25
2005-01-25
Bugaisky, Gabriele (Department: 1653)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S009100, C530S300000, C530S317000, C530S324000, C530S825000
Reexamination Certificate
active
06846804
ABSTRACT:
A sublancin peptide variant having a Gly-His peptide sequence fused to the C-terminal end of the mature sublancin peptide provides an affinity tag facilitating increased purification of the peptide variant from sample preparations without affecting the intracellular processing of the sublancin peptide variant, expression by a host cell or its biological activity in secreted form. This sublancin variant has specific inhibitory activity for spore outgrowth as for the native sublancin peptide. Production of the sublancin peptide variant on an industrial scale is set forth as are methods of decontaminating spore-infected areas. Methods for generating the peptide variant gene, plasmid and transformant are also described.
REFERENCES:
patent: 5218101 (1993-06-01), Hansen
patent: 5516682 (1996-05-01), Hansen
patent: 5576420 (1996-11-01), Hansen
patent: 5861275 (1999-01-01), Hansen
patent: 5885811 (1999-03-01), Hansen
patent: 6143498 (2000-11-01), Olsen et al.
patent: 6153405 (2000-11-01), Hansen
patent: WO 0039152 (2000-07-01), None
Paik et al. 1998. Identification and characterization of the structural and transporter genes for, and the chemical and biological properties of, sublancin 168, a novel lantibiotic produced byBacillus subtilis168. J. Biol. Chem. 273:23134-23142.*
Hawley et al. 2001. Biological weapons: A primer for microbiologists.Annual Review of Microbiology 55:235-253.*
Inglesby et al. 1999 Anthrax as a biological weapon: Medical and Public Health Management. JAMA (Journal of the American Medical Association) 281 (18): 1735-1745.*
Kupke et al. 1997. In vivo reaction of affinity tag labelled epidermin precursor peptide with flavoenzyme EpiD. FEMS Microbiology Letters 153:25-32.*
Callard et al. (1994) The cytokine Factsbook. San Diego:Academic Press p. 22.*
Hansen, “Nisin and Related Antimicrobial Peptides”, Biotechnology of Antibiotics, Second Edition, pp. 437-467 (ed) W. Strohl. New York: Marcel Dekker, Inc. (1997).
Arent & Fox PLLC
Bugaisky Gabriele
University of Maryland, College Park Office of Technology Commer
LandOfFree
Construction of a structural variant of sublancin to... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Construction of a structural variant of sublancin to..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Construction of a structural variant of sublancin to... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3423863